Founded in 2009 and headquartered in Elche (Alicante), Spain, Bioarray is a leading diagnostic and research laboratory specializing in advanced genetic analysis. Leveraging cutting-edge molecular biology technologies – including array-CGH and Next Generation Sequencing (NGS) – Bioarray supports both clinical and research applications in reproductive genetics, oncology, and medical genetics.

With a strong foothold in Europe and Latin America and clients across more than 40 countries, Bioarray has earned a reputation for high-quality, reliable genetic testing services. The company primarily serves public and private hospitals, reproductive clinics, and research institutions, providing tailored solutions backed by a deep understanding of genetic science and exceptional bioinformatics capabilities.

Bioarray offers a comprehensive range of services, including preimplantation genetic testing, expanded carrier screening, endometrial receptivity analysis, and prenatal diagnostics within reproductive genetics. In the field of medical genetics, the company provides whole exome and whole genome sequencing, along with customized gene panels for conditions such as rare diseases, neurological disorders, and metabolic syndromes. Its oncology portfolio includes somatic and germline cancer testing, liquid biopsies, and molecular tumor profiling. Beyond diagnostics, Bioarray is a trusted research partner, delivering gene expression analysis, RNA sequencing, microRNA and methylation studies.

By combining scientific excellence, technological innovation, and a customer-focused mindset, Bioarray empowers healthcare providers and researchers to deliver faster, more accurate, and highly personalized insights in the fast-growing field of genetic diagnostics.